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Abstract
Background: HER2/neu-positive breast cancer cells have recently been shown to use a unique Warburg-like
metabolism for survival and aggressive behavior. These cells exhibit increased fatty acid synthesis and storage
compared to normal breast cells or other tumor cells. Disruption of this synthetic process results in apoptosis.
Since the addition of physiological doses of exogenous palmitate induces cell death in HER2/neu-positive breast
cancer cells, the pathway is likely operating at its limits in these cells. We have studied the response of HER2/neu-
positive breast cancer cells to physiological concentrations of exogenous palmitate to identify lipotoxicity-
associated consequences of this physiology. Since epidemiological data show that a diet rich in saturated fatty
acids is negatively associated with the development of HER2/neu-positive cancer, this cellular physiology may be
relevant to the etiology and treatment of the disease. We sought to identify signaling pathways that are
regulated by physiological concentrations of exogenous palmitate specifically in HER2/neu-positive breast cancer
cells and gain insights into the molecular mechanism and its relevance to disease prevention and treatment.
Methods: Transcriptional profiling was performed to assess programs that are regulated in HER2-normal MCF7
and HER2/neu-positive SKBR3 breast cancer cells in response to exogenous palmitate. Computational analyses
were used to define and predict functional relationships and identify networks that are differentially regulated in
the two cell lines. These predictions were tested using reporter assays, fluorescence-based high content
microscopy, flow cytometry and immunoblotting. Physiological effects were confirmed in HER2/neu-positive
BT474 and HCC1569 breast cancer cell lines.
Results: Exogenous palmitate induces functionally distinct transcriptional programs in HER2/neu-positive breast cancer
cells. In the lipogenic HER2/neu-positive SKBR3 cell line, palmitate induces a G2 phase cell cycle delay and CHOP-
dependent apoptosis as well as a partial activation of the ER stress response network via XBP1 and ATF6. This response
appears to be a general feature of HER2/neu-positive breast cancer cells but not cells that overexpress only HER2/neu.
Exogenous palmitate reduces HER2 and HER3 protein levels without changes in phosphorylation and sensitizes HER2/
neu-positive breast cancer cells to treatment with the HER2-targeted therapy trastuzumab.
Conclusions: Several studies have shown that HER2, FASN and fatty acid synthesis are functionally linked. Exogenous
palmitate exerts its toxic effects in part through inducing ER stress, reducing HER2 expression and thereby sensitizing
cells to trastuzumab. These data provide further evidence that HER2 signaling and fatty acid metabolism are highly
integrated processes that may be important for disease development and progression.
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Background
Approximately 20 % of all breast cancers have increased
expression of the ERBB2 (HER2/neu) oncogene [1]. This
overexpression is often due to chromosomal amplifica-
tion and is associated with resistance to chemotherapy,
increased recurrence and worse prognosis [2]. Several
studies have shown that a number of genes are fre-
quently co-overexpressed or co-amplified along with
HER2/neu [1–5]. Several of these co-overexpressed
genes have been shown in functional genomics studies
to be required for HER2/neu-positive breast cancer cell
survival. Since many of these critical genes have roles in
fat metabolism and adipogenesis, HER2/neu-positive
breast cancer cells possess higher levels of stored triacyl-
glycerides (TAGs) as well as higher levels of saturated
fatty acids compared to other cell types [6, 7].
The lipogenic metabolism of HER2/neu-positive breast
cancer cells may represent a therapeutic opportunity
and have consequences that impact treatment (reviewed
recently [8, 9]). The pro-adipogenic transcriptional regu-
lators, PPARγ binding protein (PBP) and RevERBα/
NR1D1 cooperatively contribute to increased expression
of pro-lipogenic enzymes and a unique, Warburg-like
metabolism in HER2/neu-positive breast cancer cells [6].
Overexpression of HER2 itself has also previously been
shown to have pro-lipogenic effects translationally in-
creasing protein production of acetyl-CoA carboxylase
alpha (ACACA) and fatty acid synthase (FASN) [10].
The result of these genetic changes is the constant pro-
duction of fatty acids as a means to regenerate reducing
equivalents for glycolysis. This occurs through the
concerted action of malic enzyme (ME1) and malate
dehydrogenase (MDH1), while PBP, NR1D1 and
PPARγ orchestrate the sequestration of fatty acids in
neutral lipids to avoid lipotoxicity [6, 7]. Since the
addition of physiological concentrations of exogenous
saturated fatty acids, such as palmitate, induces cell
death in HER2/neu-positive breast cancer cells at sig-
nificantly lower concentrations than in other breast
cancer cells or normal human mammary epithelial
cells (HMECs) [7], the lipogenic pathway is likely op-
erating at maximum capacity in these cells. This sen-
sitivity of HER2/neu-positive breast cancer cells to
palmitate may be related to new epidemiological data
that shows that a diet rich in saturated fatty acids is
positively associated with the development of HER2/
neu-negative disease, but not HER2/neu-positive
disease [11]. By modeling the lipotoxicity associated
consequences of this physiology we sought to identify
signaling pathways that are regulated by physiological
concentrations of exogenous palmitate in HER2/neu-
positive breast cancer cells and gain insights into the
molecular mechanism and its relevance to disease
prevention and treatment.
Methods
Cell culture and chemicals
Breast cancer cell lines SKBR3, BT474, HCC1569, MCF7
and MCF10A were obtained from the American Type
Culture Collection (Manassas, VA, USA) in 2011. Cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Hyclone, Logan, UT) supplemented with 10 %
fetal bovine serum (Hyclone) at 37 °C and 5 % CO2.
MCF10A cells were cultured and infected with pLXSN-
neu or vector control retroviruses as previously de-
scribed [6]. All cell lines were authenticated in March
2016 by the SUNY-Albany Center for Functional
Genomics Molecular Core Facility using a short tandem
repeat method (Promega GenePrint 10 system). The
IRE1 inhibitor STF803010 was obtained from EMD
Millipore (Billerica, MA). Trastuzumab was a generous
gift from Genentech (San Francisco, CA). Sodium palmi-
tate, MG132 and 4-phenyl butyrate (4-PBA) were ob-
tained from Sigma-Aldrich (St. Louis, MO). Palmitate
was solubilized in DMSO or ethanol and diluted in full
growth medium (DMEM, 10 % FBS) prior to the treat-
ment of cells. The palmitate concentration was chosen
based on the sensitivity profiles of the different HER2/
neu-positive breast cancer cell lines. 250 μM palmitate
leads to a 70–80 % reduction in viability in SKBR3 cells.
According to the literature, fasting FFA concentrations in
plasma/serum are in the range of 300–600 μM [12–14]
with palmitate representing about one quarter of the total
FFAs [15, 16]. However, these concentrations vary exten-
sively based on the analysis method used for quantifica-
tion [16]. Based on these studies, 250 μM palmitate was
deemed to be in the physiological range. All solutions
were prepared immediately before usage. For nuclei
counts, cells were plated in 96-well plates and allowed to
adhere overnight. After treatment and incubation cells
were fixed with 2.5 % formaldehyde and nuclei were
stained with 1 μg/mL Hoechst 33342 (Life Technologies,
Grand Island, NY). Images of cells were acquired using
the INCell Analyzer 2200 high-content imaging system
and images were analyzed using the INCell Investigator
software (GE Healthcare, Piscataway, NJ). For anchorage-
independent growth cells were seeded in ultra-low attach-
ment plates in the presence of 250 μM palmitate or
vehicle control and incubated for 11 days. Viable cells
were assessed using the Alamar Blue cell health indicator
assay (Life Technologies, Grand Island, NY) [17].
Microarray analysis
After 24 h of treatment with 250 μM palmitate or ve-
hicle control, cells were harvested by trypsinization and
total RNA was extracted using the RNeasy mini kit
(Qiagen, Valencia, CA). The quality and the concentra-
tions of total RNA were assessed using the Agilent Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA). Total
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RNA (100 ng) deemed to be of good quality (RNA integ-
rity number (RIN) greater than 8) was processed accord-
ing to the standard Affymetrix Whole Transcript Sense
Target labeling protocol (Affymetrix, Santa Clara, CA).
The fragmented biotin-labeled cDNA from three inde-
pendent biological replicates was hybridized over 16 h to
Affymetrix Gene 1.0 ST arrays and scanned on an
Affymetrix Scanner 3000 7G using AGCC software. The
resulting CEL files were analyzed for quality using
Affymetrix Expression Console software and were
imported into GeneSpring GX11.5 (Agilent Technolo-
gies) where the data was quantile normalized using
PLIER and baseline transformed to the median of the
control samples. The probe sets were further filtered to
exclude the bottom 20th percentile across all samples as
well as probe sets with expression levels with CV > 20 %
across all replicates in a condition. The resulting entity
list was subjected to a t-test with Benjamini-Hochberg
FDR correction. The data files have been deposited in
Array Express, Accession number: E-MTAB-2601.
Metabolic assays
For detection of neutral fat stores, cells were stained with
1 μg/ml 4,4-difluoro1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacence (BODIPY 493/503; Life Technologies,
Grand Island, NY). Cells were grown in 96-well plates,
fixed with 2.5 % formaldehyde, stained with 1 μg/ml BOD-
IPY 493/503 and counterstained for nuclei with 1 μg/mL
Hoechst 33342. Cells were imaged using the INCell
Analyzer 2200 (GE Healthcare, Piscataway, NJ) high-
content imaging system. Images were analyzed using the
INCell Investigator software.
Apoptosis assays
Induction of apoptosis was assessed as described previ-
ously using Apo-BrdU staining of fragmented DNA [18].
Treated and control cells were harvested by trypsiniza-
tion and fixed with 4 % formaldehyde in PBS for 20 min
on ice, followed by permeabilization with 70 % EtOH
overnight at -20 °C. The 3′-OH ends of fragmented
DNA were enzymatically labeled with bromodeoxyuri-
dine triphosphate (Br-dUTP, Phoenix Flow Systems, San
Diego, CA), using terminal deoxynucleotidyl transferase
(Roche Applied Science) in TdT reaction buffer contain-
ing 2.5 mM cobalt chloride (Roche Applied Science) for
1 h at 37 °C. Br-dUTP labeled fragmented DNA was de-
tected using a FITC-conjugated anti-BrdU monoclonal
antibody (1:20,BD Pharmingen, San Jose, CA). Cells
were counterstained with 5 μg/mL propidium iodide
(Sigma-Aldrich) in the presence of 0.015 U/mL RNase
(Roche Applied Science) in PBS with 0.1 % Triton X-100
for 30 min at room temperature. Samples were analyzed
on a BD LSR II Flow Cytometer (BD Biosciences, San
Jose, CA). Percentage of dead cells was assessed by
propidium iodide uptake. Cells were trypsinized and in-
cubated in PBS containing 5 μg/mL propidium iodide
(Sigma-Aldrich) for 15 min. PI content was determined
by flow cytometry. Three independent biological repli-
cates and a minimum of 10,000 events were acquired for
each experimental condition. The data were analyzed
using the FlowJo software package (Treestar Inc.,
Ashland, OR).
Cell cycle analysis
Cell cycle analysis was performed as described previ-
ously [19], briefly, the cells were treated for 24 h with
palmitate or vehicle control and harvested by trypsiniza-
tion, followed by 90 % ethanol permeabilization over-
night at -20 °C. Permeabilized cells were stained with
5 μg/mL propidium iodide (Sigma-Aldrich) in the pres-
ence of 0.015 U/mL RNase (Roche Applied Science) in
PBS for 20 min at room temperature. Data were acquired
on a BD LSR II Flow Cytometer (BD Biosciences, San Jose,
CA) with a minimum of 10,000 events collected for each
experimental condition and analyzed using the FlowJo
software package (Treestar Inc., Ashland, OR).
Immunoblotting
Immunoblots were performed using standard protocols.
Cells were lysed directly in Laemmli loading buffer, pro-
teins were resolved by SDS-PAGE and transferred to
PVDF membranes (EMD Millipore, Billerica, MA).
Membranes were blocked in Tris buffered saline (TBS)
containing 0.1 % Tween and 5 % non-fat powdered milk
(TBS-T, 5 % milk). Primary antibody incubation was per-
formed in TBS-T, 5 % milk overnight at 4 °C. Proteins
were visualized using a species-specific HRP-conjugated
secondary antibody and the ECL Plus chemifluorescent
detection system (Thermo Fisher Scientific Inc.,
Waltham, MA) on a STORM scanner ((GE Healthcare,
Piscataway, NJ). Signal was quantified using ImageJ soft-
ware ((https://imagej.nih.gov/). The following primary
antibodies were used: PERK (#5683, Cell Signaling Tech-
nology, Inc., Danvers, MA)(1:1000), phospho-PERK
(Thr980, #3179, Cell Signaling) (1:1000), PDI (#3501, Cell
Signaling) (1:1000), BiP (#3177, Cell Signaling) (1:1000),
eIF2α (#5324, Cell Signaling) (1:1000), phospho-eIF2α
(Ser51, #3398, Cell Signaling) (1:1000), DDIT3/CHOP
(#2895, Cell Signaling) (1:500), HER2 (#4290, Cell Signal-
ing), phospho-HER2 (Tyr1221/1222, #2243, Cell Signal-
ing) (1:1000), HER3 (#4754, Cell Signaling) (1:1000),
phospho-HER3 (Tyr1289, #4791, Cell Signaling) (1:1000),
EGFR (#4267, Cell Signaling) (1:1000), phospho-EGFR
(Tyr1068, #3777, Cell Signaling) (1:1000), GAPDH
(#5174, Cell Signaling) (1:15000), α-tubulin (MCA78G,
AbD Serotec, Oxford, UK) (1:15000). Secondary anti-
bodies: goat-anti-rabbit-HRP (#7074, Cell Signaling)
(1:5000), horse-anti-mouse-HRP (#7076, Cell Signaling)
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(1:5000), goat-anti-rat-HRP (sc-2303, Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) (1:15000).
Statistical and computational analyses
The impact of molecular perturbations (inhibitors,
shRNAs) on breast cancer cell phenotypes including cell
survival, proliferation, apoptosis resistance, was mea-
sured in three independent experiment, from replicate
cultures. Means and standard deviations were calculated
and results were analyzed for statistical significance
using Student’s t-tests for pairwise comparisons or one-
way ANOVA with Bonferroni post test, when more than
two experimental groups were compared. P values < 0.05
were considered statistically significant.
Gene ontology (GO) enrichment analysis was carried
out using the DAVID Bioinformatics Resource [20, 21].
Logistic regression analysis for transcription factor motif
enrichment was performed using the free web service
LRPath (http://lrpath.ncibi.org/). LRpath functionally re-
lates the odds of gene set membership (dependent vari-
able) with the statistical significance of differential
expression (independent variable) using logistic regres-
sion, and calculates q-values using the FDR method as a
measure of statistical significance [22]. The False discov-
ery rate (FDR) is a statistical method when performing
multiple comparisons used to control the expected pro-
portion of rejected null hypotheses that were incorrect
rejections (“false discoveries”) [23]. The network neigh-
borhood of enriched transcription factors was obtained
by querying the STRING database [24].
Transfections and reporters
For pCAX-XBP1-ΔDBD-venus reporter construct assays
[25], cells were seeded in 96-well plates and allowed to
adhere overnight before they were transfected using
XtremeGene HP (Roche), according to the manufac-
turer’s instructions. Cells were treated as indicated in the
individual experiments, 24 h post-transfection. Expres-
sion of the fluorescent protein is indicative of IRE1-
mediated XBP1 splicing. The pCAX-XBP1-ΔDBD-venus
reporter construct was a generous gift from Dr.
Masayuki Miura, University of Tokyo. shRNA-mediated
knockdown experiments were carried out using pSM2
constructs obtained from Open Biosystems. Transfec-
tions were performed as described for pCAX-XBP1-
ΔDBD-venus experiments and cells were treated 48 h
post-transfection. Proteasome activity was tested using
the ZsProSensor-1 reporter construct which utilizes the
ZsGreen1 fluorescent protein coupled to a proteasome-
targeting sequence (Clontech, Mountain View, CA).
Accumulation of fluorescence in the cell is indicative of
decreased proteasome activity.
Results
Physiological concentrations of saturated fat induce
distinct responses in breast cancer cells
The HER2-normal cell line MCF7 and the HER2/neu-
positive SKBR3 cell line were used to investigate the dif-
ferential effects of low concentrations of exogenous
palmitate. The use of MCF7 cells as a control is prefera-
ble since they can be grown in the same cell culture
medium as SKBR3 cells and previous studies have
shown that the response to exogenous palmitate in
MCF7 cells is comparable to that of non-tumorigenic
MCF10A mammary epithelial cells or normal human
mammary epithelial cells (HMECs) [7, 26]. We cultured
MCF7 and SKBR3 cells in the presence of either 250 μM
palmitate or vehicle control and monitored cell count as
well as the levels of intracellular neutral fat stores. We
chose this concentration based on previous studies
showing that fasting FFA concentrations in plasma/
serum are in the range of 300–600 μM [12–14] with
palmitate representing about one quarter of the total
FFAs [15, 16]. Exogenous palmitate rapidly reduces the
number of SKBR3 cells, but not MCF7 cells. These ef-
fects are mediated by the effects of palmitate on cellular
physiology and not as effects on cellular integrity which
are not seen at concentrations in this range (Additional
file 1: Figure S1). While SKBR3 cells show higher basal
levels of stored neutral fats that do not change with
palmitate treatment, MCF7 cells display low basal neu-
tral fat content which increases significantly upon palmi-
tate exposure (Fig. 1a, b). Under anchorage-independent
growth conditions exogenous palmitate appears to be
beneficial to the growth of MCF7 cells but detrimental
to that of SKBR3 cells (Fig. 1c).
To identify transcriptional programs and signaling net-
works that mediate the response to exogenous palmitate
in HER2/neu-positive and HER2-normal breast cancer
cells we performed microarray analysis. SKBR3 and
MCF7 cells were treated with 250 μM palmitate or ve-
hicle control for 24 h, total RNA was isolated and hy-
bridized to Affymetrix Gene ST 1.0 arrays. Figure 2a
shows a heatmap representation of the transcripts that
display at least 1.5-fold change in expression. In MCF7
cells, 34 genes are upregulated and 80 genes are down-
regulated in response to palmitate treatment. Whereas
in SKBR3 cells, 154 genes show increased expression
and 91 genes show decreased expression. Additionally,
the extent of the transcriptional changes is more pro-
nounced in the SKBR3 cells compared to MCF7 cells.
The transcripts that are modulated by exogenous palmi-
tate are also remarkably different between the two cell
types (Fig. 2b), with only one gene being jointly upregu-
lated and six shared genes in the downregulated group.
We performed gene ontology (GO) enrichment ana-
lysis using the DAVID Bioinformatics Resource to
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investigate which transcriptional programs are regulated
in the two cell lines in response to exogenous palmitate
[20, 21]. Figure 2c shows the results of a functional
annotation clustering analysis which combines similar
GO-terms into clusters. The enrichment score for each
cluster indicates the significance compared to the whole
dataset. Upregulated GO-terms in MCF7 cells show lit-
tle, if any, functional enrichment, with the most enriched
GO-terms being related to “extracellular” (ES: 1.19) and
“intermediate filament” (ES: 1.08). Upregulated GO-
terms in SKBR3 cells however cluster around terms
related to “ER-Golgi-membrane (ES: 5.09), ”ER stress/
unfolded protein (ES: 3.89) and “regulation of apoptosis”
(ES: 3.47), indicating the induction of ER stress as well
as apoptotic signaling.
A detailed list of the enriched GO-terms for up-and
downregulated genes in both cell lines can be found in
the supplementary material (Additional file 1: Figure S2
and Additional file 1: Figure S3). Of note, in SKBR3
cells, exogenous palmitate significantly attenuates pro-
cesses related to DNA replication, cell cycle and cell
division (Additional file 1: Figure S3). We used the
Cytoscape plugin Enrichment Map to better visualize
the functional relationships between the significantly
enriched GO-terms in SKBR3 cells, as well as illustrate
gene member overlap (Additional file 1: Figure S4). The
top clusters “ER stress/UPR”, “apoptosis” and “cell cycle”
are immediately apparent from the map. To further elu-
cidate the transcriptional response to exogenous palmi-
tate in SKBR3 cells we performed gene set enrichment
analysis (GSEA) [27, 28]. Genes that show increased ex-
pression after palmitate treatment in SKBR3 cells over-
lap significantly with genes that are upregulated after
proteasome inhibition by epoxomicin, supporting the
claim of an ER stress/UPR response in the SKBR3 cells
(Additional file 1: Figure S5). However, palmitate does
not directly affect proteasome activity in SKBR3 cells
(Additional file 1: Figure S6). Genes that are downregu-
lated in SKBR3 cells after palmitate treatment overlap
significantly with a group of genes that show decreased
expression after growth factor deprivation (Additional
file 1: Figure S5).
Fig. 1 HER2/neu-positive SKBR3 and HER2-normal MCF7 cells differ in their response to palmitate. a, b HER2/neu-positive SKBR3 and HER2-normal
MCF7 breast cancer cells were treated with 250 μM palmitate or vehicle for 24 h and 48 h. Cells were fixed and neutral lipids were stained with
BODIPY 493/503. Nuclei were stained with Hoechst 33342. BODIPY fluorescence and nuclei were imaged and quantified using the INCell Analyzer
2200 and INCell Investigator software. C16 = palmitate. c Exogenous palmitate alters anchorage-independent growth. Cells were plated in ultra-
low attachment plates in the presence of 250 μM palmitate or vehicle control and incubated for 11 days. Viable cells were quantified using the
Alamar Blue cell health indicator. Statistical analysis was carried out in Graphpad Prism. Data are presented as mean ± SD. * = p · 0.05, ** = p · 0.01,
*** = p · 0.001, Student’s t-test, n = 3, n = 4 in C
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Palmitate induces G2-phase cell cycle delay and apoptosis
in HER2/neu-positive SKBR3 breast cancer cells
The computational analysis suggests that exogenous
palmitate induces changes in cell cycle regulation as well
as apoptotic signaling, so we performed cell cycle ana-
lysis by flow cytometry. As expected, the HER2-normal
MCF7 breast cancer cells show no changes in the cell
cycle phase distribution, comparing palmitate-treated
and vehicle-treated cells. HER2/neu-positive SKBR3 cells
however show a significant delay in the G2 phase of the
cell cycle when treated with exogenous palmitate
(Fig. 3a). Induction of apoptosis was assessed by ter-
minal deoxynucleotidyl transferase-mediated DNA-end
labeling with ApoBrdU, whereas cell death was moni-
tored by propidium iodide (PI) uptake. Exogenous
palmitate causes a significant increase in DNA fragmen-
tation in HER2/neu-positive SKBR3 cells, but has no
effect on HER2/neu-normal MCF7 cells (Fig. 3b). The
PI-positive SKBR3 cell population increases significantly
as well (Fig. 3c). This indicates that exogenous palmitate
induces apoptosis and cell death in HER2/neu-positive
SKBR3 cells but not HER2/neu-normal MCF7 cells,
confirming the predictions made by the functional
enrichment analyses.
Logistic Regression analysis identifies transcription factor
binding motif enrichment for XBP1 and ATF6
To further elucidate which transcriptional programs are
activated by palmitate in the HER2/neu-positive SKBR3
breast cancer cell line, we performed logistic regression
analysis using the LRPath web resource [22]. By query-
ing the TRANSFAC database, the algorithm can identify
significantly enriched transcription factor binding motifs
in the up- and downregulated gene groups. We identi-
fied the transcription factors ATF6 (FDR q-value: 2.69 ×
10-3) and XBP1 (FDR q-value: 3.43 × 10-3) as the two
Fig. 2 Exogenous palmitate induces a distinct transcriptional response in HER2/neu-positive SKBR3 breast cancer cells. HER2/neu-positive SKBR3
and HER2-normal MCF7 breast cancer cells were treated with 250 μM palmitate or vehicle for 24 h. C16 = palmitate. Total RNA was harvested and
subjected to microarray analysis using Affymetrix Gene ST 1.0 arrays. a Heatmap showing log2-ratios of altered transcripts between vehicle and
palmitate treated samples (1.5-fold cut-off). b Venn diagram showing the number of genes that are up- or downregulated with palmitate treatment in
SKBR3 and MCF7 cells (1.5-fold cut-off). c Results of the Functional Annotation Clustering analysis after GO-term enrichment of upregulated genes
using the DAVID Bioinformatics Resource
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most significantly enriched motifs in the upregulated
genes. The two most significantly enriched transcription
factor binding motifs in the downregulated genes are
currently not known to be bound by any particular tran-
scription factor (Table 1). ATF6 and XBP1 are both
known regulators of the ER stress and unfolded protein
response (UPR) [29]. The two transcription factors were
used as input for the STRING database of protein inter-
actions to retrieve the immediate network neighborhood
[24], which is shown as a Cytoscape network in Fig. 4a.
ATF6 expression increases significantly in palmitate-
treated SKBR3 cells, however, no changes in XBP1
mRNA levels were detected (Fig. 2 and Fig. 4).We used
a transcriptional reporter construct described by Samali
et al. to evaluate whether exogenous palmitate is able to
induce XBP1 splicing, which is associated with the acti-
vation of ER stress [25]. MCF7 and SKBR3 cells were
transfected with the pCAX-XBP1-ΔDBD-venus vector
which results in the expression of a functional fluores-
cent XBP1-venus fusion protein if the XBP1 mRNA is
Fig. 3 Palmitate induces G2-phase cell cycle delay and apoptosis in HER2/neu-positive SKBR3 breast cancer cells. a MCF7 and SKBR3 cells were
treated with 250 μM palmitate or vehicle for 24 h. C16 = palmitate. Cells were ethanol-fixed and DNA content was analyzed by propidium iodide
staining and flow cytometry analysis. Cell cycle phases were determined using FlowJo software. b MCF7 and SKBR3 cells were treated with
250 μM palmitate or vehicle for 48 h, fixed in paraformaldehyde and subjected to Apo-BrdU DNA end-labeling. A FITC-labeled anti-BrdU antibody
was used to detect incorporated BrdU by flow cytometry. c MCF7 and SKBR3 cells were treated with 250 μM palmitate or vehicle for 24 h. Dead
cells were monitored for propidium iodide uptake via flow cytometry. Data were analyzed using FlowJo software and normalized to control
conditions. Statistical analysis was carried out in Graphpad Prism. Data are presented as mean ± SD. * = p · 0.05, ** = p · 0.01, Student’s t-test, n = 3
Table 1 Results of the logistic regression analysis using LRPath
Gene-set ID # of genes Hits p-Value FDR Regulation Transcription factor
ATF6_01 93 34 2.23 × 10-5 2.69 × 10-3 up ATF6
XBP1_01 152 58 4.27 × 10-5 3.43 × 10-3 up XBP1
E2F_02 96 96 1.05 × 10-14 2.54 × 10-12 down N/A
NFY Q6 26 16 1.06 × 10-3 3.65 × 10-2 down N/A
A ranked list consisting of up- and downregulated genes in HER2/neu-positive SKBR3 cells after palmitate treatment was used as input for a logistic regression
pathway analysis (LRPath) to determine enriched transcription factor binding motifs based on the TRANSFAC database. The table shows the two most significantly
enriched motifs in the upregulated and downregulated gene groups, as well as the associated transcription factors. N/A indicates that no known transcription
factor is associated with this particular motif
Baumann et al. BMC Cancer  (2016) 16:551 Page 7 of 15
spliced by the ER stress activator, IRE1. The DNA-
binding domain has been deleted from the reporter con-
struct to prevent the fusion-protein from interfering
with the function of the endogenous XBP1(s) protein.
Twenty-four hours post-transfection, the cells were chal-
lenged with exogenous palmitate for 24 h either alone or
in the presence of the IRE1 inhibitor STF803010 and
fluorescent cells were counted. While both cell lines
show low levels of XBP1 splicing in control conditions,
only the HER2/neu-positive SKBR3 cells exhibit a sig-
nificant increase in IRE1-dependent XBP1 splicing after
palmitate treatment (Fig. 4b). These data indicate that
exogenous palmitate induces IRE1-mediated XBP1 spli-
cing in the HER2/neu-positive SKBR3 cells, but not the
HER2/neu-normal MCF7 cells, confirming, in part, the
computational predictions.
Exogenous palmitate increases DDIT3/CHOP expression in
HER2/neu-positive SKBR3 cells
The activation of IRE1 and ATF6, two of the three major
regulators of ER stress, and the computational predic-
tions suggest that the activation of a canonical ER stress
response occurs in SKBR3 cells exposed to exogenous
palmitate. We performed western blot analyses for other
proteins that are known to be involved in the ER stress
and unfolded protein response pathways to further
evaluate these predictions (Fig. 5a). Interestingly, we did
not detect any changes in the protein levels or relative
phosphorylation levels for the third major regulator of
ER stress, PKR-like endoplasmic reticulum kinase
(PERK). The primary substrate of PERK is the eukaryotic
translation initiation factor 2 alpha (eIF2α), a critical
regulator of translation and the unfolded protein re-
sponse. Upon activation, PERK phosphorylates eIF2α,
which attenuates global protein synthesis and leads to
the preferred translation of stress response-related tran-
scripts. In accordance with the results for PERK activa-
tion, palmitate treatment does not induce any changes
in eIF2α protein expression or relative phosphorylation
levels in either MCF7 or SKBR3 cells. Protein disulfide
isomerase (PDI) and GRP78/BiP, both known to be in-
volved in the unfolded protein response, are not in-
creased at the protein level with palmitate treatment in
either cell line. There is, however, a substantial increase
Fig. 4 Logistic Regression analysis determines transcription factor binding motif enrichment for XBP1 and ATF6. a Interaction network adapted from
the STRING database showing the immediate network neighborhood of the two enriched transcription factors ATF6 and XBP1 obtained through the
analysis described in Table 1. Big nodes indicate input genes, red nodes indicate increased expression, green nodes indicate decreased expression as
identified in the microarray analysis described in Fig. 2. Grey nodes are part of the interaction network but were not identified in the microarray results.
b MCF7 and SKBR3 cells were transfected with the transcriptional reporter construct pCAX-XBP1-ΔDBD-venus which results in the expression of a
functional fluorescent XBP1-venus fusion protein after mRNA splicing by the ER stress regulator IRE1. STF803010 inhibits the RNase activity of IRE1 (+ =
10 μM). The cells were treated with 250 μM palmitate 24 h post-transfection, alone or in combination with STF803010 and green fluorescent cells were
counted using the InCell Analyzer 2200. C16 = palmitate. The data were normalized to control conditions and are presented as mean ± SD. ** = p · 0.01,
One-way ANOVA with Bonferroni post-test. n = 3
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in the expression of the pro-apoptotic regulator of ER
stress and the unfolded protein response, DDIT3/CHOP,
in SKBR3 cells. Treatment with exogenous palmitate
increases DDIT3/CHOP protein levels in the HER2/neu-
positive SKBR3 cells by approximately 2-fold, whereas
HER2/neu-normal MCF7 cells are not affected (Fig. 5b).
Fig. 5 Exogenous palmitate increases DDIT3/CHOP expression in HER2/neu positive breast cancer cells. a MCF7 and SKBR3 cells were treated
with 250 μM palmitate or vehicle control for 24 h. C16 = palmitate. Total protein was harvested and subjected to western blot analysis to evaluate
the protein expression changes for the ER stress related markers PERK, phospho-PERK (pPERK, Thr980), PDI, BiP, eIF2α, phospho-eIF2α (p-eiF2α, Ser51)
and DDIT3/CHOP. Each experiment was performed in triplicate, representative images are shown. b Quantification of the DDIT3/CHOP western blots
using ImageJ. c Cells were treated with vehicle for 24 h and assessed for basal levels of DDIT3, normalized to MCF7 levels. Quantification of DDIT3
mRNA levels after treatment with 500 μM sodium palmitate for 24 h. The data are presented as mean ± SEM of three independent experiments.
d SKBR3 cells were transfected with an shRNA targeting DDIT3/CHOP or luciferase, which has no target in these cells. 48 h post-transfection the cells
were treated with 250 μM palmitate or vehicle for 24 h and nuclei were counted using the INCell Analyzer 2200. e MCF7 and SKBR3 cells
were treated with 250 μM palmitate or vehicle either alone or in the presence of the chemical chaperone 4-PBA for 24 h. Nuclei were
counted and the data were normalized to control conditions. Data are presented as mean ≤ SD. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.
One-way ANOVA with Bonferroni post-test. n = 3
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Analysis of MCF7 and SKBR3 cells showed that they
have similar basal levels of DDIT3/CHOP. Notably,
other HER2/neu-positive breast cancer cell lines, BT474
and HCC1569, have elevated DDIT3/CHOP mRNA
levels under standard growth growth conditions. Treat-
ment with palmitate increased DDIT3/CHOP mRNA
levels greater than 20-fold in SKBR3 cells with a lesser
induction seen in HCC1569 and BT474, most likely due
to their high basal levels (Fig. 5c). A similar situation
existed with levels of ATF6 and spliced XBP1 in the
HCC1569 and BT474 cells which were significantly in-
creased compared to MCF7 cells but exhibited relatively
modest levels of induction due to palmitate (Additional
file 1: Figure S7).
Since DDIT3/CHOP is known to induce pro-apoptotic
signaling we investigated whether the increase in
DDIT3/CHOP expression with palmitate treatment is
responsible for the increase in cell death in the SKBR3
cell line. Cells were transfected with an shRNA construct
targeting DDIT3 or luciferase as a control and were sub-
sequently treated with palmitate or vehicle control
(Fig. 5d). Knockdown of DDIT3/CHOP significantly re-
duces the cytotoxic effects of exogenous palmitate in
SKBR3 cells, compared to the palmitate-treated and con-
trol-transfected conditions. However, the protection con-
ferred by DDIT3/CHOP knockdown is not complete as
there is a significant difference between the palmitate-
treated DDIT3/CHOP -knockdown cells and vehicle-
treated cells, indicating that other factors besides DDIT3/
CHOP might contribute to the toxic effects of exogenous
palmitate in HER2/neu-positive SKBR3 breast cancer
cells. These data corroborate the induction of ER stress/
UPR in SKBR3 cells treated with exogenous palmitate, as
predicted by our computational analyses. Additionally,
despite the genetic heterogeneity of HER2/neu-positive
breast cancer [1], aspects of this response may occur gen-
erally in HER2/neu-positive breast cancer cell lines which
our previous work has shown undergo apoptosis when
cultured with exogenous palmitate [6, 7]. To investigate
whether unfolded or misfolded proteins contribute to the
toxic effects of palmitate in these cells we used the chem-
ical chaperone 4-phenylbutyric acid (4-PBA), which is able
to increase the protein folding capacity of the ER and at-
tenuate the unfolded protein response [30]. SKBR3 cells
display a dose dependent attenuation of palmitate-
induced cytotoxicity when 4-PBA is co-administered with
palmitate, whereas MCF7 cells show no change related to
the addition of 4-PBA (Fig. 5e).
To determine whether ER stress induction might
occur in tumors, we analyzed molecular profiling data
sets of invasive breast carcinomas generated by the
TCGA Research Network: http://cancergenome.nih.gov/
[1]. Analysis of these data reveal an association between
ER stress regulators and the regulators of the lipogenic
phenotype previously described in HER2/neu-positive
breast cancer cell lines [6, 7]. Statistically significant
greater than twofold increases in expression in ER stress
pathway genes are found to co-occur with increased
levels of HER2/neu, NR1D1 and PBP in human breast
tumors (Additional file 1: Figure S8). In this data set, ap-
proximately 15 % of the tumors exhibit increased ex-
pression of HER2/neu. 43 % of tumors that exhibit
increased expression of PERK and 39 % of tumors that
exhibit increased expression of IRE1 are found in the
HER2/neu increased expression group. 53 % of the tu-
mors that overexpress HER2/neu, NR1D1 and PBP to-
gether also overexpress one or more ER stress marker.
The importance of these statistically significant associa-
tions is difficult to interpret unequivocally since the in-
creased expression of each ER stress marker seems to be
somewhat independent and since the cellular compos-
ition of tumors is generally heterogeneous. However,
it lends support to the notion that the frequent in-
crease in lipogenesis that occurs in HER2/neu-positive
breast cancers may trigger some degree of ER stress
response in vivo.
Palmitate decreases HER2 and HER3 expression and
sensitizes the cells to trastuzumab treatment
Based on the GSEA analysis, genes that display de-
creased expression after palmitate treatment in HER2/
neu-positive SKBR3 cells significantly overlap with genes
that are downregulated after growth factor deprivation
(Additional file 1: Figure S5). A probable cause for these
transcriptional changes in HER2/neu-positive cells is the
deregulation of HER2 signaling after palmitate treat-
ment. To test this hypothesis, we evaluated protein ex-
pression changes in the HER-family of receptor tyrosine
kinases in palmitate-treated SKBR3 cells by western blot.
Exogenous palmitate induces a significant reduction in
the HER2 and HER3 protein levels, while EGFR expres-
sion (HER1) and phosphorylation is unaffected. Interest-
ingly, the relative phosphorylation levels of HER3
remain unchanged as well, indicating a reduction in total
HER3 as well as active, phosphorylated HER3 (Fig. 6a,
b). The relative phosphorylation of HER2 may be in-
creased by palmitate treatment; however the differences
are not significant. Previous studies have shown that
HER2 and HER3 heterodimerize and form the predom-
inant and most potent mitogenic combination in carcin-
oma cells [31–33], hence we investigated whether these
particular effects of exogenous palmitate on HER2/neu-
positive SKBR3 breast cancer cells are able to increase
the efficacy of trastuzumab treatment. SKBR3 cells were
pretreated with different doses of palmitate (150 μM and
250 μM) or vehicle control for 24 h. The palmitate-
containing medium was removed and replaced with
fresh medium containing 22 μg/mL trastuzumab [19] or
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vehicle control and the cells were incubated for an add-
itional 48 h. Palmitate significantly increases the growth
inhibitory effects of trastuzumab compared to vehicle
control (Fig. 7). This effect is also found to occur in the
HER2/neu-positive breast cancer cell line, BT474. The
somewhat attenuated effect in BT474 cells is congruent
with our observations that BT474 cells are less sensitive
to exogenous palmitate than SKBR3 cells. In either case,
the growth inhibitory and ER stress inducing effects of
palmitate on HER2/neu-positive breast cancer cells are
not caused by the decrease in HER2 and HER3 levels.
Overexpression of HER2/neu in a normal breast line
Fig. 6 Exogenous Palmitate decreases HER2 and HER3 expression in HER2/neu-positive SKBR3 cells. a SKBR3 cells were treated with 250 μM
palmitate or vehicle for 24 h. C16 = palmitate. Total protein was harvested and subjected to western blot analysis to evaluate the protein
expression changes for the HER-family proteins HER2, phospho-HER2 (p-HER2, Tyr1221/1222), HER3, phospho-HER3 (pHER3, Tyr1289)), EGFR and
phospho-EGFR (pEGFR,Tyr1068). Each experiment was performed in triplicate, representative images are shown. b Quantification of the HER2,
pHER2, HER3 and pHER3 western blots using ImageJ. c Intensities were normalized to loading control and vehicle-control. The data is presented
as mean · SD. * = p · 0.05, ** = p · 0.01, *** = p · 0.001. Student’s t-test. n = 3
Fig. 7 Exogenous palmitate sensitizes HER2/neu-positive cells to trastuzumab. The HER2/neu-positive breast cancer cell lines SKBR3 and BT474
were treated with 22 μg/mL trastuzumab for 48 h either with palmitate (+ = 150 μM, ++ = 250 μM) or vehicle pre-treatment. C16 = palmitate.
Nuclei were counted using the INCell Analyzer 2200. The data were normalized to 48 h trastuzumab alone and are presented as mean · SD. * = p ·
0.05, ** = p · 0.01, *** = p · 0.001. One-way ANOVA with Bonferroni post-test. n = 3
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does not by itself counteract the effects of palmitate on
reducing cell numbers (Additional file 1: Figure S9A).
Similarly, the induction of ER stress markers after palmi-
tate treatment is largely unaffected by HER2/neu overex-
pression (Additional file 1: Figure S9B). Together, these
results provide additional evidence for a link between
fatty acid synthesis and HER2/neu function to what is
already known [6, 10, 34, 35]. Additionally, they are con-
sistent with previous work showing that the lipogenic
phenotype of HER2/neu-positive breast cancer cells is
dependent on genes other than HER2/neu itself [6, 7]. It
will undoubtedly take additional experimentation to un-
ravel the signaling interactions related to the effects of
palmitate on HER2 and HER3 levels.
Discussion
Our previous work has shown that HER2/neu-positive
breast cancer cells contain high levels of endogenous
saturated fatty acids and neutral lipids and generally
exhibit a pro-lipogenic phenotype [6–9, 19]. This
Warburg-like physiology relies on active fatty acid syn-
thesis for survival and aggressive behavior. Since small
amounts of exogenously supplied palmitate are toxic to
HER2/neu-positive breast cancer cells, however, this
phenotype might represent an Achilles heel [7]. In this
study, we used physiological concentrations of exogen-
ous palmitate both to investigate molecular mechanisms
of lipotoxicity associated with this Warburg-like physi-
ology and to model high levels of dietary saturated fat.
We identified pathways that are modulated by exogen-
ous palmitate in the HER2/neu-positive SKBR3 breast
cancer cell line and compared this response to that of
HER2-normal MCF7 breast cancer cells, which have pre-
viously been shown to respond to exogenous palmitate
in a way that is comparable to non-tumorigenic
MCF10A mammary epithelial cells or normal human
mammary epithelial cells (HMECs) [7, 26]. This analysis
was extended to additional HER2/neu-positive breast
cancer cell lines and publicly available molecular profil-
ing data of human breast tumors.
Exogenous palmitate induces distinct transcriptional
responses in SKBR3 and MCF7 cells, which are congru-
ent with the severity of the observed toxicity (Fig. 2 and
[6]). Most notably in HER2/neu-positive SKBR3 cells,
exogenous palmitate induces a partial ER stress response
through the activation of the IRE1-XBP1 and ATF6 axes,
but not the PERK-eIF2α axis, which ultimately leads to
CHOP-dependent cell death (Fig. 5). Increased levels of
ER stress response markers are also found in HER2/neu-
positive breast cancer cell lines and human breast tu-
mors. The general trend of the three HER2/neu-positive
breast cancer cell lines tested was that they possessed
higher basal levels of DDIT3/CHOP, ATF6 and spliced
XBP1 and that these levels increased in response to
palmitate treatment (Additional file 1: Figure S7). These
effects were not observed in the other breast cells tested.
Additionally, analysis of molecular profiling data sets of
invasive breast carcinomas generated by the TCGA Re-
search Network [1] revealed an association between the
ER stress markers and the HER2/neu, NR1D1 and PBP
genes linked to lipogenesis [6–9, 19] in human breast tu-
mors (Additional file 1: Figure S8). Together, these data
point to ER stress as a potential consequence of in-
creased palmitate levels in HER2/neu-positive breast
cancer cells, although the precise pathway may not be
clear at present. Several studies have reported that
palmitate induces ER stress responses in liver and pan-
creatic beta-cells. Cao et al. report that palmitate induces
ER stress and apoptosis in liver cells through the activa-
tion of PERK/ATF4/CHOP [36]. Sommerweis et al. ob-
tained similar results in pancreatic beta-cells, where
palmitate induced PERK activation and eIF2α phosphor-
ylation but no upregulation of ATF6 was detected [37].
These studies have identified palmitate induced ER
stress pathways that are somewhat different from what
we have found in the HER2/neu-positive breast cancer
cells. However, the overexpression of HER2, which has
been linked to increased sensitivity towards ER stress-
inducing agents [38], may complicate the interpretation.
Similar to our results, Young et al. report saturated fatty
acid-induced ER stress and CHOP-dependent cell
death in mouse embryonic fibroblasts (MEFs) with
consitutively active mTOR signaling when the cells
are cultured under hypoxic conditions [39]. mTOR
signaling is frequently activated in HER2/neu-positive
breast cancer cells and tumors and may contribute to
the lipotoxicity observed in HER2/neu-positive SKBR3
cells (reviewed in [9]).
Determination of the molecular mechanism of palmitate
in inducing ER stress and reducing HER2/HER3 levels will
require additional study. Previous studies have suggested
that exogenous palmitate exerts its toxic effects through
the dysregulation of protein palmitoylation. Baldwin et al.
found that palmitate-induced ER stress and apoptosis in
beta-cells could be ameliorated by adding the palmitoyla-
tion inhibitor 2-bromopalmitate [40] and the ER-resident
chaperone, calnexin, has been shown to be functionally
regulated by palmitoylation. Upon ER stress induction,
palmitoylation of calnexin decreases, which promotes its
chaperone function [41]. However, this does not appear to
be a relevant mechanism in HER2/neu-positive breast
cancer cells. 2-bromopalmitate appears to be even more
toxic to these cells than palmitate (Baumann et al., unpub-
lished observations). These results are consistent with a
metabolic effect as 2-bromopalmitate inhibits a variety of
enzymes, some of which are required for TAG formation,
a process that has been shown to be critical for the sur-
vival of HER2/neu-positive breast cancer cells [6, 7, 42].
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Given the altered metabolic phenotype of HER2/neu-
positive breast cancer cells, which rely on active fatty
acid synthesis for survival [6, 7], it is possible that ex-
ogenous palmitate induces ER stress and decreases
HER2/HER3 protein levels indirectly by interfering with
FA synthesis. Upon uptake into the cell, palmitate is
converted into palmitoyl-CoA which is a major allo-
steric feedback inhibitor of ACACA, the rate-limiting
enzyme in fatty acid synthesis [43]. The inhibition of
fatty acid synthesis caused by palmitate (Baumann et al.
unpublished) may have effects on growth factor signal
transduction. Several lines of investigation have linked
HER2 and fatty acid synthase (FASN) previously.
ACACA and FASN are upregulated in HER2/neu-posi-
tive breast cancers at the transcriptional [6] and the
translational level [10]. Overexpression of FASN in im-
mortalized, non-tumorigenic mammary epithelial cells
has been shown to induce HER2 overexpression and
activation [34] and there are reports that FASN may be
directly phosphorylated by HER2 [35]. Additionally,
pharmacological inhibition of FASN induces ER stress
[44], decreases HER2 protein levels [45, 46], sensitizes
cells to trastuzumab treatment [46] and reverses ac-
quired autoresistance to trastuzumab [47, 48]. All of
these findings are consistent with our observations that
exogenous palmitate induces ER stress, decreases HER2
and HER3 protein levels and sensitizes the cells to
trastuzumab-mediated growth inhibition. These data
suggest that exogenous palmitate may function, at least
in part, as a feedback inhibitor of fatty acid synthesis in
HER2/neu-positive breast cancer cells, as well as an ER
stress inducer. Since prolonged activation of the ER
stress response has previously been linked to increased
sensitivity to various chemotherapeutic agents, includ-
ing trastuzumab [49] as we see (Fig. 7), levels of palmi-
tate in the breast cancer microenvironment may have
positive impacts on treatment. Along these lines, high
levels of dietary saturated fatty acids may be capable of
interfering with HER2 expression and signaling during
disease development. While many studies have shown a
protective effect of polyunsaturated fatty acids on
breast cancer development in general, elevated levels of
saturated fat may impose a metabolic constraint that
specifically decreases the development of HER2/neu-
positive breast cancer - a situation consistent with
recent epidemiological studies [11]. Although
consumption of high levels of saturated fat is not an
envisioned therapy, further investigation of this
phenomenon may lead to an improved understanding
of breast cancer cell physiology. In any event, this study
provides further evidence that HER2 signaling, fatty
acid metabolism and ER stress signaling are highly inte-
grated processes that may be important for disease de-
velopment and progression.
Conclusions
We have shown that physiological concentrations of ex-
ogenous palmitate induce a partial ER stress response and
CHOP-dependent apoptosis in HER2/neu-positive breast
cancer cells. This ER stress response is accompanied by a
significant reduction in HER2 and HER3 protein levels
and sensitizes cells to trastuzumab treatment. These data
provide further evidence that HER2 signaling and fatty
acid metabolism are highly integrated processes that may
be important for disease development and progression.
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